MEDEXUS PHARMACEUTICALS INC


Associated tags: TSX, Patient, Pharmaceutical industry, Methotrexate, Hematopoietic stem cell transplantation, Hematology, Customer service, Blood, Treosulfan, Rheumatoid arthritis, Allergy, Health Canada, FDA, Collaboration, World Health Organization, Glioma

Medexus Announces DTC Eligibility of its Common Shares in the United States

Retrieved on: 
Thursday, August 15, 2019

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements).

Key Points: 
  • Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements).
  • The words anticipates, believes, expects, will, and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
  • Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of the date hereof.
  • Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.